...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Study to Evaluate HER2-neu Expressionin Different Histopathological Gradesof Prostatic Carcinoma in aTertiary Care Centre, Bareilly
【24h】

Study to Evaluate HER2-neu Expressionin Different Histopathological Gradesof Prostatic Carcinoma in aTertiary Care Centre, Bareilly

机译：巴约塞（Starily）研究患者2-Neu成分不同组织病理学阶段的癌症癌

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Prostate cancer is the second most common neoplasm among men around the world. Two routinely used immunocytochemical markers for prostatic epithelium are Prostatic Acid Phosphatase (PAP) and Prostatic Specific Antigen (PSA). Various other markers like Prostate-Specific Membrane Antigen (PSMA), androgen and progesterone receptors, HER2- neu, low molecular weight keratin, etc., are also used. HER2-neu overexpression has been implicated in tumorigenesis and has been correlated with a poor prognosis for patients with breast cancer, ovarian cancer, and gastric cancer. Use of Trastuzumab for the treatment of breast carcinoma has improved prognosis in HER2-neu positive cases. Recent studies have suggested the correlation of HER2-neu overexpression with higher grades of prostate cancer.Aim: To study HER2-neu expression in different histopathological grades of prostatic carcinoma.Materials and Methods: A prospective study was carried out on 41 histopathologically proven cases of prostatic carcinoma in Pathology Department of SRMSIMS, Bareilly over a period of one year and six months (November 2017 to April 2019). Gleason grading and HER2-neu Immunohistochemistry was applied on every case and then correlated. Statistical tests were applied, statistical software Statistical Package for the Social Sciences (SPSS) version 21.Results: A 92.7% (38/41) cases were reported as Prostatic Adenocarcinoma of Non-Mucinous type. Total of 42.5% (17/40) were grouped under Grade group 5, 27.5% (11/40) cases under Grade group 3 and 10% (4/40) under Grade groups 1,2 and 4 each. Out of total, 14.6% (6/41) cases were considered as positive and 80.5% (33/41) cases were considered as negative for HER2-neu expression and 4.9% (2/41) cases were considered as equivocal (Fluorescence In Situ Hybridization (FISH) conformation required). In cases with positive HER2-neu expression, mean group grade was calculated to be 4.83?±0.40 and in patients with negative HER2-neu expression, it was 3.38±1.40 (it was calculated to find correlation between group grade and HER2-neu expression). There was a significant statistical difference (p=0.00003668) found between the Gleason Group Grade in HER2-neu positive and negative patients as HER2-neu positivity is seen in higher group grades. One case was reported as neuroendocrine carcinoma in which Gleason grading was not done.Conclusion: Compared to low Gleason Group Grade carcinoma, higher percentage of HER2-neu expression was seen in high Gleason Group grade carcinoma.
机译：前列腺癌是世界各地男性中最常见的肿瘤。用于前列腺上皮的两种定期使用的免疫细胞化学标志物是前列腺酸磷酸酶（PAP）和前列腺特异性抗原（PSA）。还使用各种其他标记物，如前列腺特异性膜抗原（PSMA），雄激素和孕酮受体，HER2- NEU，低分子量角蛋白等。 Her2- Neu过表达涉及肿瘤发生，并与乳腺癌，卵巢癌和胃癌的患者的预后不良。使用曲妥珠单抗用于治疗乳腺癌在HER2-NEU阳性病例中具有改善的预后。最近的研究表明Her2-Neu过度表达与较高等级的前列腺癌相关的相关性。目的：研究不同组织病理学等级的前列腺癌中的HER2- NEU表达。材料和方法：进行了一项前瞻性研究在一年和六个月（2017年11月至2019年4月）的Srmsims病理科病理科病理癌前列腺癌前列腺癌的组织病理学癌症案。在每种情况下都施加了Glason分级和Her2-Neu免疫组化，然后相关。应用统计测试，社会科学统计软件统计包（SPSS）版本21. 结果：92.7％（38/41）病例报告为非粘液类型的前列腺腺癌。总共42.5％（17/40）在第5级，27.5％（11/40）患者在第3级和10％（4/40）下，在等级组1,2和4的10％（4/40）下。总共有14.6％（6/41）病例被认为是阳性的，80.5％（33/41）案件被认为是Her2-Neu表达的阴性，4.9％（2/41）案件被认为是等常数的（荧光所需的原位杂交（鱼类）构象）。在阳性Her2-Neu表达的情况下，平均群体等级计算为4.83？±0.40，并且在负Her2-neu表达患者中，它为3.38±1.40（计算出在群体等级和Her2-Neu表达之间的相关性）。在HER2-NEU阳性和阴性患者的GLEAN组级和阴性患者中，在高等群体等级中看到的患者阳性和阴性阳性之间存在显着的统计学差异（p = 0.00003668）。一个病例被报告为神经内分泌癌，其中没有完成Glason分级。结论：与低压术群级癌，相比，在高玻璃群级癌中看到了较高的HER2-Neu表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号